A Study of Depemokimab in Participants of 6 to 11 Years of Age

Sponsor
GlaxoSmithKline
Study ID
NCT07671001
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
6 Years - 11 Years
Healthy Volunteers
Not accepted

Interventions

  • Depemokimab — BIOLOGICAL
    Depemokimab will be administered.

Study Details

This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age. This study will test how the body processes depemokimab, how the drug works in the body, and its safety and tolerability.

Key Dates

First listed
Jun 26, 2026
Start date
Jun 26, 2026
Status verified
Jun 2026
Primary completion
Mar 19, 2029
Completion
Mar 19, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Depemokimab
    Participants will receive depemokimab at doses based on their body weight.

Primary Outcome Measure

Depemokimab Concentration in Plasma [ Time Frame: Up to Week 52 ]

Central Contacts

Related Studies